Related Experiment Videos
Modelling atypical CYP3A4 kinetics: principles and pragmatism
J Brian Houston1, Aleksandra Galetin
1Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester, Ml3 9PL, United Kingdom. Brian.Houston@man.ac.uk <Brian.Houston@man.ac.uk>
Archives of Biochemistry and Biophysics
|December 8, 2004
Summary
The Michaelis-Menten model often fails for drug metabolizing enzymes like CYP3A4 due to complex kinetics. Multisite models better explain these atypical behaviors, improving predictions of drug clearance and interactions.
Area of Science:
- Biochemistry
- Pharmacokinetics
- Enzyme kinetics
Background:
- The Michaelis-Menten model with a single active site is widely used for enzyme kinetics.
- Atypical kinetic behaviors are increasingly observed with drug metabolizing enzymes, particularly CYP3A4.
- These atypical kinetics include autoactivation, substrate inhibition, and concentration-dependent effector responses.
Purpose of the Study:
- To address the limitations of single-site models in explaining complex enzyme kinetics.
- To explore the utility of multisite kinetic models for drug metabolizing enzymes.
- To improve the prediction of drug clearance and drug-drug interactions from in vitro data.
Main Methods:
- Reviewing existing approaches: naive (Michaelis-Menten), empirical (Hill, uncompetitive), and mechanistic.
- Developing and applying multisite kinetic models (2-3 binding sites) for CYP3A4.
- Analyzing in vitro data from hepatocytes, microsomes, and heterologous expression systems.
Main Results:
- Single-site models are inadequate for many observed enzyme kinetic phenomena.
- Multisite kinetic models provide a more comprehensive explanation for atypical behaviors.
- These models can be simplified into generic, applicable versions.
Conclusions:
- Multisite kinetic models are essential for accurately interpreting complex enzyme kinetics.
- Failure to account for multisite kinetics compromises predictions of human drug metabolism and interactions.
- Further application of multisite models is crucial for drug development.